Medical devices, healthcare technology and the business of care
PMA approval · P240045

Optimum Infinite (tisilfocon A) Orthokeratology Lenses II

Contamac, Ltd. · Decision date Feb 10, 2026

FDA DECISIONP240045

What did the FDA approve?

FDA records P240045 as an original PMA application. The recorded decision is approval, dated Feb 10, 2026.

FDA approval order statement

Approval for Optimum Infinite (tisilfocon A) Ortho-k Lenses, Optimum Infinite (tisilfocon A) Orthokeratology Lenses II.
Regulatory pathway
Original PMA
Clinical specialty
Ophthalmic
Decision date
Feb 10, 2026

FDA source record

Regulatory record facts

Identifier
P240045
Regulatory pathway
Premarket approval application
Product code
NUU
Decision code
APPR
Decision date
Feb 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lens, contact, orthokeratology, overnight.

Product code
NUU
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240045 received

    Application receipt date recorded by FDA.

  2. P240045 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P240045. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code NUU

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Contamac, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Carlton House, Shire Hill, Saffron Walden, CB11 3AU

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records